All News Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Market Closed - Nyse Other stock markets 04:00:02 2024-04-30 pm EDT			5-day change	1st Jan Change
43.94 ^USD	-1.57%		-10.31%	-14.36%

Apr. 30	Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla...
Apr. 30	A flurry of corporate results ahead of the Fed's rate decision

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla...	Apr. 30
A flurry of corporate results ahead of the Fed's rate decision	Apr. 30
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American...	Apr. 30
Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb	Apr. 30	CI
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	Apr. 30	RE
J&J, Bristol Myers lose challenges to US drug price negotiation program	Apr. 29	RE
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60	Apr. 29	MT
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating	Apr. 29	MT
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases	Apr. 29	PR
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases	Apr. 29	CI
S&P 500 Q1 earnings estimated growth improves; stocks up for week	Apr. 26	RE
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51	Apr. 26	MT
UBS Cuts Bristol-Myers Squibb Price Target to $47 From $52, Maintains Neutral Rating	Apr. 26	MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $51	Apr. 26	MT
JPMorgan Adjusts Bristol-Myers Squibb's Price Target to $60 From $65	Apr. 26	MT
Bristol-Myers Squibb Says European Regulator Recommends Approval of Bladder Cancer Combination Therapy	Apr. 26	MT
Bristol Myers: positive opinion from the CHMP for Opdivo	Apr. 26	CF
Bristol Myers Gets CHMP Backing for Opdivo Combo in Bladder Cancer	Apr. 26	DJ
Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb Company to $37 From $40	Apr. 26	MT
Truist Cuts Price Target on Bristol-Myers Squibb to $64 From $68, Keeps Buy Rating	Apr. 26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST